To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

Bill 117 hr 4278, titled "To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes," aims to investigate the impact of direct-to-consumer pharmaceutical advertising on the costs of prescription drugs for consumers.

The bill directs the Comptroller General of the United States to conduct a comprehensive study on how direct-to-consumer pharmaceutical advertising contributes to the rising costs of prescription drugs. The study will examine the various ways in which advertising directly to consumers affects drug pricing, including how it may influence consumer demand and pricing strategies by pharmaceutical companies.

The bill also seeks to explore any potential negative consequences of direct-to-consumer pharmaceutical advertising, such as increased healthcare costs for consumers, overprescribing of medications, and the potential for misleading or inaccurate information in advertisements. Overall, the purpose of Bill 117 hr 4278 is to gather data and insights on the impact of direct-to-consumer pharmaceutical advertising on drug costs and consumer behavior. This information will be crucial in informing future policy decisions aimed at addressing rising prescription drug prices and ensuring that consumers have access to affordable and effective medications.